Clinical Predictors for Hepatocellular Carcinoma in Patients With Primary Biliary Cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 2, 2007, Pages 259-264

  Suzuki, Ayako ^a,b   Lymp, James ^c   Donlinger, Jessica ^a   Mendes, Flavia ^a   Angulo, Paul ^a   Lindor, Keith ^a  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEMOGLOBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANALYTIC METHOD; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL INFORMATION; MULTIVARIATE ANALYSIS; PORTAL HYPERTENSION; PREDICTION; PRIMARY BILIARY CIRRHOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK;

ADULT; AGE FACTORS; AGED; BLOOD TRANSFUSION; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS;

EID: 33846837288     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.09.031     Document Type: Article

References (26)

1. Kim W.R., Lindor K.D., Locke III G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 119 (2000) 1631-1636
2. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 335 (1996) 1570-1580
3. Corpechot C., Carrat F., Bonnand A.M., et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32 (2000) 1196-1199
4. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128 (2005) 297-303
5. Loof L., Adami H.O., Sparen P., et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. Hepatology 20 (1994) 101-104
6. Van Dam G.M., and Gips C.H. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol 32 (1997) 77-83
7. Jones D.E., Metcalf J.V., Collier J.D., et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 26 (1997) 1138-1142
8. Nijhawan P.K., Therneau T.M., Dickson E.R., et al. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 29 (1999) 1396-1398
9. Shibuya A., Tanaka K., Miyakawa H., et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. Hepatology 35 (2002) 1172-1178
10. Floreani A., Baragiotta A., Baldo V., et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology 29 (1999) 1425-1428
11. Howel D., Metcalf J.V., Gray J., et al. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 45 (1999) 756-760
12. Sorensen H.T., Friis S., Olsen J.H., et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28 (1998) 921-925
13. Caballeria L., Pares A., Castells A., et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96 (2001) 1160-1163
14. Bruix J., Sherman M., Llovet J.M., et al., European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
15. Angulo P., Lindor K.D., Therneau T.M., et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 19 (1999) 115-121
16. Ikeda K., Saitoh S., Koida I., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18 (1993) 47-53
17. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48 (2001) 251-259
18. Bruno S., Silini E., Crosignani A., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 25 (1997) 754-758
19. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 (1991) 675-680
20. Degos F., Christidis C., Ganne-Carrie N., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000) 131-136
21. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 45 Suppl 3 (1998) 1206-1213
22. Fattovich G., Giustina G., Schalm S.W., et al., The EUROHEP study group on hepatitis B virus and cirrhosis. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 21 (1995) 77-82
23. Fattovich G., Pantalena M., Zagni I., et al. European Concerted Action on Viral H. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 97 (2002) 2886-2895
24. Realdi G., Fattovich G., Hadziyannis S., et al., The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 21 (1994) 656-666
25. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328 (1993) 1797-1801
26. Sarasin F.P., Giostra E., and Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101 (1996) 422-434